Physicians' Academy for Cardiovascular Education

Inflammation Expert Opinions

This series of Inflammation Expert Opinions is aimed to provide different perspectives and opinions from experts commenting on potential implications from recent research targeting inflammation in cardiovascular disease. More to come...

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

Aug. 27, 2017

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

Aug. 27, 2017

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

A new challenge for precision medicine: selecting major contributing risk factors

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

After 23 years, CANTOS trial shows that inflammatory hypothesis is right

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

Anti-inflammatory therapy that does not affect thrombosis or LDL-c, can beneficially impact arterial disease

Aug. 28, 2017 - ESC 2017, Barcelona, Spain

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

Aug. 28, 2017

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

Inflammation expert opinions

Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Il prof. Raffaele De Caterina spiega perché CANTOS è uno studio clinico importante. E’ il primo studio clinico che dimostra che un farmaco anti-infiammatorio influenza favorevolmente importanti eventi cardiovascolari, e pertanto può diventare una terapia da inserire nell’armamentario terapeutico in aggiunto agli attuali trattamenti.

Inflammation Expert Opinions Il prof. Raffaele De Caterina spiega perché CANTOS è uno studio clinico importante. E’ il primo studio clinico che dimostra che un farmaco anti-infiammatorio influenza favorevolmente importanti eventi cardiovascolari, e pertanto può diventare una terapia da inserire nell’armamentario terapeutico in aggiunto agli attuali trattamenti.

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

Inflammation expert opinions

Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Prof. Raffaele de Caterina explains why CANTOS is an important trial. It is the first trial showing that an anti-inflammatory drug can affect important CV outcomes and thus may be a convenient therapy in addition to current treatment strategies.

Inflammation Expert Opinions Prof. Raffaele de Caterina explains why CANTOS is an important trial. It is the first trial showing that an anti-inflammatory drug can affect important CV outcomes and thus may be a convenient therapy in addition to current treatment strategies.

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

Inflammation expert opinions

Aug. 27, 2017
According to prof. Ulf Landmesser, the CANTOS trial shows that inflammation is crucial for disease progression and that targeting inflammation as a risk factor may have important implications for high-risk populations.

Inflammation Expert Opinions According to prof. Ulf Landmesser, the CANTOS trial shows that inflammation is crucial for disease progression and that targeting inflammation as a risk factor may have important implications for high-risk populations.

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

Inflammation expert opinions

Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Prof. Ulf Landmesser: Die CANTOS Studie zeigt erstmalig, dass eine Interleukin-1 Beta Inhibition, d.h. eine spezifische Entzündungshemmung, das kardiovaskuläre Risiko nach akutem Koronarsyndrom reduzieren kann.

Inflammation Expert Opinions Prof. Ulf Landmesser: Die CANTOS Studie zeigt erstmalig, dass eine Interleukin-1 Beta Inhibition, d.h. eine spezifische Entzündungshemmung, das kardiovaskuläre Risiko nach akutem Koronarsyndrom reduzieren kann.

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

Sep. 29, 2017 - ESC 2017, Barcelona, Spain
Prof. Wolfgang Koenig: Die CANTOS Studie belegt dass inflammatorische Prozesse eine kausale Rolle in der Atherogenese spielen. Inhibition der Inflammation führt zu einer weiteren Reduktion des kardiovaskulären Risikos ohne Beeinflussung des Lipidstatus.

Inflammation Expert Opinions Prof. Wolfgang Koenig: Die CANTOS Studie belegt dass inflammatorische Prozesse eine kausale Rolle in der Atherogenese spielen. Inhibition der Inflammation führt zu einer weiteren Reduktion des kardiovaskulären Risikos ohne Beeinflussung des Lipidstatus.

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

Inflammation expert opinions

Sep. 29, 2017 - ESC 2017, Barcelona, Spain
Prof. Wolfgang Koenig states that the CANTOS trial shows that inflammation plays a causal role in the atherogenic process.

Inflammation Expert Opinions Prof. Wolfgang Koenig states that the CANTOS trial shows that inflammation plays a causal role in the atherogenic process. Blocking this inflammation may be an additional treatment option beyond lipid lowering for CV risk reduction.

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

Inflammation expert opinions

Aug. 29, 2017 - ESC 2017, Barcelona, Spain
Lina Badimon explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation.

Inflammation Expert Opinions Lina Badimon explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation. The results of CANTOS can be the dawn of a new era of CV prevention.

A new challenge for precision medicine: selecting major contributing risk factors

Inflammation expert opinions

Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Erik Stroes summarizes the results from CANTOS and states that for daily clinical practice, it is important to select the major factors contributing to CV risk

Inflammation Expert Opinions Erik Stroes summarizes the results from CANTOS and states that for daily clinical practice, it is important to select the major factors contributing to CV risk

Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione

Aug. 29, 2017 - ESC 2017, Barcelona, Spain
Filippo Crea riflette su una pubblicazione del 1994, introducendo l’ ipotesi sull’infiammazione e spiega come lo studio CANTOS confermi tale ipotesi.

Inflammation Expert Opinions Filippo Crea riflette su una pubblicazione del 1994, introducendo l’ ipotesi sull’infiammazione e spiega come lo studio CANTOS confermi tale ipotesi. La sfida ora è individuare i pazienti che trarranno beneficio da questo trattamento.

After 23 years, CANTOS trial shows that inflammatory hypothesis is right

Inflammation expert opinions

Aug. 29, 2017 - ESC 2017, Barcelona, Spain
Filippo Crea reflects on a publication from 1994, introducing the inflammatory hypothesis, and explains how the CANTOS trial confirms this hypothesis.

Inflammation Expert Opinions Prof Filippo Crea reflects on a publication from 1994, introducing the inflammatory hypothesis, and explains how the CANTOS trial confirms this hypothesis. The challenge is now to identify patients who will benefit from this treatment.

Anti-inflammatory therapy that does not affect thrombosis or LDL-c, can beneficially impact arterial disease

Inflammation expert opinions

Aug. 28, 2017 - ESC 2017, Barcelona, Spain
Philippe Gabriel Steg reflects on the CANTOS trial results that confirm the long-standing hypothesis that inflammation plays a role in CV events and he considers which questions remain to be answered before broad clinical application of this concept.

Inflammation Expert Opinions Philippe Gabriel Steg reflects on the CANTOS trial results that confirm the long-standing hypothesis that inflammation plays a role in CV events and he considers which questions remain to be answered before broad clinical application of this concept.

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

Inflammation expert opinions

Aug. 28, 2017
Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.

Inflammation Expert Opinions Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.

Inflammation Expert Opinions
Inflammation Expert Opinions